Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

83 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
The relationship between cognitive impairment and in vivo metabolite ratios in patients with clinical Alzheimer's disease and vascular dementia: a proton magnetic resonance spectroscopy study.
Waldman AD, Rai GS. Waldman AD, et al. Neuroradiology. 2003 Aug;45(8):507-12. doi: 10.1007/s00234-003-1040-y. Epub 2003 Jul 22. Neuroradiology. 2003. PMID: 12879326
This study reinforces the specific association between reduced NAA and increased MI levels in the parieto-occipital region and cognitive impairment in AD. MRS may have a role in evaluating disease progression and therapeutic monitoring in AD, as new treatments becom …
This study reinforces the specific association between reduced NAA and increased MI levels in the parieto-occipital region and cognitive imp …
MRI of the brain with ultra-short echo-time pulse sequences.
Waldman A, Rees JH, Brock CS, Robson MD, Gatehouse PD, Bydder GM. Waldman A, et al. Neuroradiology. 2003 Dec;45(12):887-92. doi: 10.1007/s00234-003-1076-z. Epub 2003 Sep 24. Neuroradiology. 2003. PMID: 14508620
Clinical brain proton magnetic resonance spectroscopy for management of Alzheimer's and sub-cortical ischemic vascular dementia in older people.
Waldman AD, Rai GS, McConnell JR, Chaudry M, Grant D. Waldman AD, et al. Arch Gerontol Geriatr. 2002 Sep-Oct;35(2):137-42. doi: 10.1016/s0167-4943(02)00014-6. Arch Gerontol Geriatr. 2002. PMID: 14764351
D.: 0.71 +/- 0.07, P<0.00001) and normal subjects (mean +/- S.D.: 0.72 +/- 0.036, P<0.0002); there was little overlap between the AD and vascular groups. ...These data suggest that MI/Cr ratios can distinguish patients with AD from normal subjects and those wi …
D.: 0.71 +/- 0.07, P<0.00001) and normal subjects (mean +/- S.D.: 0.72 +/- 0.036, P<0.0002); there was little overlap between the A
1H-MRS evaluation of metabolism in Alzheimer's disease and vascular dementia.
Jones RS, Waldman AD. Jones RS, et al. Among authors: waldman ad. Neurol Res. 2004 Jul;26(5):488-95. doi: 10.1179/016164104225017640. Neurol Res. 2004. PMID: 15265265 Review.
Biochemical abnormalities in Alzheimer's Disease (AD), vascular dementia (VaD) and other primary degenerative dementias have been investigated using MRS. ...Similar changes are seen in VaD; mostly in white matter, whereas in AD they predominate in cortical grey matt …
Biochemical abnormalities in Alzheimer's Disease (AD), vascular dementia (VaD) and other primary degenerative dementias have been inv …
Differential chemosensitivity of tumor components in a malignant oligodendroglioma: assessment with diffusion-weighted, perfusion-weighted, and serial volumetric MR imaging.
Jäger HR, Waldman AD, Benton C, Fox N, Rees J. Jäger HR, et al. Among authors: waldman ad. AJNR Am J Neuroradiol. 2005 Feb;26(2):274-8. AJNR Am J Neuroradiol. 2005. PMID: 15709124
Posterior reversible encephalopathy syndrome: a possible late interaction between cytotoxic agents and general anaesthesia.
Rangi PS, Partridge WJ, Newlands ES, Waldman AD. Rangi PS, et al. Among authors: waldman ad. Neuroradiology. 2005 Aug;47(8):586-90. doi: 10.1007/s00234-005-1376-6. Epub 2005 Jul 5. Neuroradiology. 2005. PMID: 15997391
Visual assessment of atrophy on magnetic resonance imaging in the diagnosis of pathologically confirmed young-onset dementias.
Likeman M, Anderson VM, Stevens JM, Waldman AD, Godbolt AK, Frost C, Rossor MN, Fox NC. Likeman M, et al. Among authors: waldman ad. Arch Neurol. 2005 Sep;62(9):1410-5. doi: 10.1001/archneur.62.9.1410. Arch Neurol. 2005. PMID: 16157748
Hippocampal atrophy was noted in 92% of AD cases but was commonly seen in other dementias and controls. A bilateral symmetrical pattern of hippocampal atrophy discriminated AD from FTLD with 47% specificity, while posterior greater than anterior gradient of atrophy …
Hippocampal atrophy was noted in 92% of AD cases but was commonly seen in other dementias and controls. A bilateral symmetrical patte …
MRS shows abnormalities before symptoms in familial Alzheimer disease.
Godbolt AK, Waldman AD, MacManus DG, Schott JM, Frost C, Cipolotti L, Fox NC, Rossor MN. Godbolt AK, et al. Among authors: waldman ad. Neurology. 2006 Mar 14;66(5):718-22. doi: 10.1212/01.wnl.0000201237.05869.df. Neurology. 2006. PMID: 16534109
BACKGROUND: Pathologic change in Alzheimer disease (AD) begins some years before symptoms. MRS has the potential to detect metabolic abnormalities reflecting this early pathologic change. Presenilin 1 (PS1) and amyloid precursor protein (APP) mutation carriers have a nearl …
BACKGROUND: Pathologic change in Alzheimer disease (AD) begins some years before symptoms. MRS has the potential to detect metabolic …
83 results
Jump to page
Feedback